Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).

When using the frequent/infrequent risk classification, there was a borderline significant reduction with tiotropium in the number of COPD exacerbations compared with salmeterol in patients classified as frequent exacerbators (RR 0.90; 95% CI 0.81–1.01; p = 0.0668; adjusted annual rates = 0.79 and 0.87 for tiotropium and salmeterol, respectively) and also in the number of COPD exacerbations compared with salmeterol in patients classified as infrequent exacerbators (RR 0.88; 95% CI 0.75–1.02; p = 0.0881; adjusted annual rates = 0.48 and 0.55 for tiotropium and salmeterol, respectively) (Fig. 2 ).

also in 11,409 other papers